US5521184A
(en)
*
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
GB9212673D0
(en)
*
|
1992-06-15 |
1992-07-29 |
Celltech Ltd |
Chemical compounds
|
US5972598A
(en)
*
|
1992-09-17 |
1999-10-26 |
Board Of Trustess Of The University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
US6171786B1
(en)
|
1992-09-17 |
2001-01-09 |
Board Of Trustees Of University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
US5728708A
(en)
*
|
1993-10-01 |
1998-03-17 |
Novartis Corporation |
Pharmacologically active pyridine derivatives and processes for the preparation thereof
|
JP3588116B2
(en)
*
|
1993-10-01 |
2004-11-10 |
ノバルティス アクチェンゲゼルシャフト |
Pharmacologically active pyrimidineamine derivatives and process for their production
|
EP0672035A1
(en)
*
|
1993-10-01 |
1995-09-20 |
Novartis AG |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5543520A
(en)
*
|
1993-10-01 |
1996-08-06 |
Ciba-Geigy Corporation |
Pyrimidine derivatives
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
GB9326699D0
(en)
*
|
1993-12-22 |
1994-03-02 |
Celltech Ltd |
Chemical compounds
|
WO1995017399A1
(en)
*
|
1993-12-22 |
1995-06-29 |
Celltech Therapeutics Limited |
Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitors
|
US5786354A
(en)
*
|
1994-06-21 |
1998-07-28 |
Celltech Therapeutics, Limited |
Tri-substituted phenyl derivatives and processes for their preparation
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
GB9412571D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412573D0
(en)
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412672D0
(en)
*
|
1994-06-23 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
US5756527A
(en)
*
|
1995-06-07 |
1998-05-26 |
Ontogen Corporation |
Imidazole derivatives useful as modulators of multi drug resistances
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526246D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0812829A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Substituted imidazoles as modulators of multi-drug resistance
|
EP0812830A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Modulators of multi-drug resistances
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
WO1998028281A1
(en)
|
1996-12-23 |
1998-07-02 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
GB9705361D0
(en)
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9713087D0
(en)
*
|
1997-06-20 |
1997-08-27 |
Celltech Therapeutics Ltd |
Chemical compounds
|
CO4940418A1
(en)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
|
GB9914258D0
(en)
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
JP2003503354A
(en)
|
1999-06-30 |
2003-01-28 |
メルク エンド カムパニー インコーポレーテッド |
SRC kinase inhibitor compounds
|
AU6605200A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
AU5636900A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
DE60023926T2
(en)
|
1999-09-10 |
2006-07-20 |
Merck & Co., Inc. |
TYROSINE KINASE INHIBITORS
|
GB9924862D0
(en)
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
CN1429222A
(en)
*
|
2000-02-17 |
2003-07-09 |
安姆根有限公司 |
Kinase inhibitors
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7087608B2
(en)
*
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
EP1315715B1
(en)
|
2000-08-18 |
2008-07-23 |
Millennium Pharmaceuticals, Inc. |
Quinazoline derivatives as kinase inhibitors
|
GB0022438D0
(en)
*
|
2000-09-13 |
2000-11-01 |
Novartis Ag |
Organic Compounds
|
PL209733B1
(en)
*
|
2000-10-27 |
2011-10-31 |
Novartis Ag |
Treatment of gastrointestinal stromal tumors
|
AU2002217999A1
(en)
|
2000-11-01 |
2002-05-15 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
AU2002250968C1
(en)
|
2001-02-19 |
2018-01-04 |
Novartis Ag |
Cancer treatment
|
SE0100569D0
(en)
*
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
New compounds
|
PT1385522E
(en)
*
|
2001-02-27 |
2009-09-04 |
Novartis Ag |
Combination comprising a signal transduction inhibitor and an epothilone derivative
|
AU2002342878A1
(en)
*
|
2001-05-16 |
2002-11-25 |
Axxima Pharmaceuticals Ag |
Pyridylpyrimidine derivatives as effective compounds against prion diseases
|
NZ529145A
(en)
|
2001-05-16 |
2005-07-29 |
Novartis Ag |
Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)- 2pyrimidine-amine and a chemotherapeutic agent
|
AU2002345670A1
(en)
|
2001-06-14 |
2003-01-02 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
EP1408978A4
(en)
|
2001-06-21 |
2005-07-13 |
Ariad Pharma Inc |
Novel phenylamino-pyrimidines and uses thereof
|
ES2255621T3
(en)
|
2001-06-22 |
2006-07-01 |
MERCK & CO., INC. |
THYROSINE KINASE INHIBITORS.
|
US7678805B2
(en)
|
2001-06-29 |
2010-03-16 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
|
CA2452368A1
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
New potent, selective and non toxic c-kit inhibitors
|
US20040266797A1
(en)
*
|
2001-06-29 |
2004-12-30 |
Alain Moussy |
Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
|
DE60212627T2
(en)
|
2001-06-29 |
2007-06-14 |
Ab Science |
Use of tyrosine kinase inhibitors for the treatment of inflammatory diseases
|
CA2452371A1
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating allergic diseases
|
WO2003039550A1
(en)
*
|
2001-09-20 |
2003-05-15 |
Ab Science |
Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
|
WO2003040141A1
(en)
*
|
2001-09-28 |
2003-05-15 |
Bayer Pharmaceuticals Corporation |
Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
|
EP2341133A1
(en)
|
2001-10-05 |
2011-07-06 |
Novartis AG |
Mutated Abl kinase domains
|
GB0201508D0
(en)
*
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
GB0202873D0
(en)
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
GB0202874D0
(en)
*
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
AU2007203463B2
(en)
*
|
2002-02-07 |
2010-12-23 |
Novartis Pharma Ag |
N-phenyl-2-pyrimidine-amine derivatives
|
AU2003209521A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Oregon Health And Science University (Ohsu) |
Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
|
EP1490067B1
(en)
*
|
2002-02-27 |
2008-09-17 |
AB Science |
Use of tyrosine kinase inhibitors for treating substance use disorders
|
WO2003072090A2
(en)
*
|
2002-02-27 |
2003-09-04 |
Ab Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
KR20040093058A
(en)
*
|
2002-02-28 |
2004-11-04 |
노파르티스 아게 |
N-(5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
AU2003231231A1
(en)
*
|
2002-05-06 |
2003-11-11 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
EP1955696B1
(en)
|
2002-05-16 |
2014-05-28 |
Novartis AG |
Use of the EDG receptor binding agent FTY720 in cancer
|
US7015227B2
(en)
|
2002-06-21 |
2006-03-21 |
Cgi Pharmaceuticals, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
AU2003295320A1
(en)
*
|
2002-06-26 |
2004-04-08 |
The Ohio State University Research Foundation |
The method for reducing inflammation using sti-571 or its salt
|
US7494997B2
(en)
*
|
2002-06-28 |
2009-02-24 |
Nippon Shinyaku Co., Ltd. |
Amide derivative
|
GB0215676D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
DE60316810T2
(en)
*
|
2002-08-02 |
2008-07-17 |
Ab Science |
2- (3-AMINOARYL) AMINO-4-ARYL-THIAZOLE AND THEIR USE AS C-KIT INHIBITORS
|
GB0222514D0
(en)
*
|
2002-09-27 |
2002-11-06 |
Novartis Ag |
Organic compounds
|
AU2003273986A1
(en)
*
|
2002-10-11 |
2004-05-04 |
Novartis Ag |
Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
US7144911B2
(en)
*
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
GB2398565A
(en)
*
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
MXPA05010628A
(en)
*
|
2003-04-04 |
2006-03-17 |
Bayco Tech Ltd |
Vascular stent.
|
WO2004099186A1
(en)
|
2003-05-06 |
2004-11-18 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
EP2644195A1
(en)
|
2003-05-19 |
2013-10-02 |
Irm Llc |
Immunosuppressant Compounds and Compositions
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
NZ543709A
(en)
*
|
2003-05-27 |
2009-04-30 |
Robert Per Hagerkvist |
Use of tyrosine kinase inhibitor to treat diabetes
|
ES2338557T3
(en)
*
|
2003-06-13 |
2010-05-10 |
Novartis Ag |
DERIVATIVES OF 2-AMINOPIRIMIDINE USED AS INHIBITORS OF RAF CINASA.
|
EP3168304A1
(en)
|
2003-08-27 |
2017-05-17 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
AU2004290902B2
(en)
|
2003-11-18 |
2008-09-25 |
Novartis Ag |
Inhibitors of the mutant form of kit
|
CN101456841B
(en)
|
2003-12-25 |
2012-01-25 |
日本新药株式会社 |
Amide derivative and medicine
|
AR047530A1
(en)
|
2004-02-04 |
2006-01-25 |
Novartis Ag |
FORMS OF SALT OF 4- (4-METHYLIPIPERAZIN-1-ILMETIL) -N- (4-METHYL-3- (4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) PHENYL) -BENZAMIDA
|
PL1720853T3
(en)
|
2004-02-11 |
2016-06-30 |
Natco Pharma Ltd |
Novel polymorphic form of imatinib mesylate and a process for its preparation
|
CN1309719C
(en)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
Derivative of phenylamide pyrimidine and application thereof
|
PL2253614T3
(en)
|
2004-04-07 |
2013-03-29 |
Novartis Ag |
Inhibitors of IAP
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
CA2578122A1
(en)
*
|
2004-08-27 |
2006-03-02 |
Gpc Biotech Ag |
Pyrimidine derivatives
|
WO2006024863A1
(en)
|
2004-09-02 |
2006-03-09 |
Cipla Limited |
Stable crystal form of imatinib mesylate and process for the preparation thereof
|
CA2591321C
(en)
|
2004-09-09 |
2013-09-24 |
Natco Pharma Limited |
Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
|
US7939541B2
(en)
*
|
2004-09-09 |
2011-05-10 |
Natco Pharma Limited |
Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
EP1833815B1
(en)
*
|
2004-12-30 |
2010-09-15 |
Instytut Farmaceutyczny |
A process for preparation of imatinib base
|
CN1972917B
(en)
*
|
2004-12-31 |
2010-08-25 |
孙飘扬 |
Aminopyrimidine compounds and their salts, process for preparation and pharmaceutical use thereof
|
CN1939910A
(en)
*
|
2004-12-31 |
2007-04-04 |
孙飘扬 |
Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
|
MX2007008810A
(en)
|
2005-01-21 |
2007-11-21 |
Astex Therapeutics Ltd |
Pharmaceutical compounds.
|
AU2006242311B2
(en)
|
2005-05-02 |
2010-03-04 |
Novartis Ag |
Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
UA96139C2
(en)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Anti-neuropilin-1 (nrp1) antibody
|
AU2006314444C1
(en)
|
2005-11-21 |
2018-01-04 |
Novartis Ag |
Neuroendocrine tumor treatment using mTOR inhibitors
|
KR20130140909A
(en)
|
2005-11-25 |
2013-12-24 |
노파르티스 아게 |
F, g, h, i and k crystal forms of imatinib mesylate
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
EP2314297A1
(en)
|
2006-04-05 |
2011-04-27 |
Novartis AG |
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
|
CN102671196B
(en)
|
2006-04-05 |
2014-12-03 |
诺华股份有限公司 |
Combinations of therapeutic agents for treating cancer
|
PE20080251A1
(en)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
USES OF DPP IV INHIBITORS
|
KR20090007635A
(en)
|
2006-05-09 |
2009-01-19 |
노파르티스 아게 |
Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
JP4417424B2
(en)
|
2006-06-01 |
2010-02-17 |
国立がんセンター総長 |
Carcinogenic inhibitor
|
JP2010504933A
(en)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pyrazolopyrimidines as PI3K lipid kinase inhibitors
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
KR20090061055A
(en)
*
|
2006-10-26 |
2009-06-15 |
시코르, 인크. |
Crystalline and amorphous imatinib base, imatinib mesylate and processes for preparation thereof
|
ES2496592T3
(en)
|
2006-11-16 |
2014-09-19 |
F.I.S.- Fabbrica Italiana Sintetici S.P.A. |
Process for the preparation of Imatinib and intermediate compounds thereof
|
CN101245061B
(en)
*
|
2007-02-13 |
2012-09-19 |
天津天士力集团有限公司 |
N-(5-amido-2-methyl phenyl)-4-(3-pyridinyl)-2-aminopyrimidine nitric oxide donating derivant, production method and uses thereof
|
EP2359818A1
(en)
|
2007-02-15 |
2011-08-24 |
Novartis AG |
Combination of LBH589 with HSP 90 inhibitors for treating cancer
|
RU2329260C1
(en)
*
|
2007-02-20 |
2008-07-20 |
Юрий Иосифович Копырин |
Method of obtaining 2-anilinopyrimidines or their salts (options)
|
BRPI0808840A2
(en)
*
|
2007-03-12 |
2014-09-02 |
Reddy S Laborartories Ltd Dr |
IMATINIB MESILATE
|
WO2008117298A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Natco Pharma Limited |
A novel method of preparation of imatinib
|
US7550591B2
(en)
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
US8367686B2
(en)
|
2007-06-07 |
2013-02-05 |
Intra-Cellular Therapies, Inc. |
Heterocycle compounds and uses thereof
|
WO2008153974A1
(en)
|
2007-06-07 |
2008-12-18 |
Intra-Cellular Therapies, Inc. |
Novel heterocycle compounds and uses thereof
|
PT2200436E
(en)
|
2007-09-04 |
2015-04-29 |
Scripps Research Inst |
Substituted pyrimidinyl-amines as protein kinase inhibitors
|
WO2009060463A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Natco Pharma Limited |
An environmentally friendly process for the preparation of imatinib base
|
EP2062885A1
(en)
*
|
2007-11-21 |
2009-05-27 |
Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. |
Acid addition salts of imatinib and formulations comprising the same
|
DK2252597T3
(en)
*
|
2008-02-01 |
2014-04-28 |
Akinion Pharmaceuticals Ab |
PYRAZINE DERIVATIVES AND THEIR USE AS PROTEINKINASE INHIBITORS
|
MX2010010525A
(en)
|
2008-03-24 |
2010-10-25 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors.
|
NZ588069A
(en)
|
2008-03-26 |
2012-06-29 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
CN101584696A
(en)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
Composition containing quinazoline derivatives, preparation method and use
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
AU2009248923B2
(en)
|
2008-05-21 |
2015-01-29 |
Takeda Pharmaceutical Company Limited |
Phosphorous derivatives as kinase inhibitors
|
PL215042B1
(en)
*
|
2008-08-01 |
2013-10-31 |
Temapharm Spolka Z Ograniczona Odpowiedzialnoscia |
Method of imatinib manufacturing
|
UY32030A
(en)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN"
|
AU2009281122C1
(en)
|
2008-08-15 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
EP2344161B1
(en)
|
2008-10-16 |
2018-12-19 |
Celator Pharmaceuticals, Inc. |
Combinations of a liposomal water-soluble camptothecin with cetuximab or bevacizumab
|
EP2186514B1
(en)
|
2008-11-14 |
2016-06-29 |
Kinki University |
Treatment of Malignant Peripheral Nerve Sheath Tumors
|
AU2009327405A1
(en)
|
2008-12-18 |
2011-06-30 |
Novartis Ag |
New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
|
BRPI0923176B8
(en)
|
2008-12-18 |
2021-05-25 |
Novartis Ag |
crystalline form of the acid hemifumarate salt of 1-(4-{1-[(e)-4-cyclohexyl-3-trifluoromethyl-benzyloxy-imino]-ethyl}-2-ethyl-benzyl)-azetidine-3- carboxylic and pharmaceutical composition
|
WO2010080455A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
New salts
|
JP2012512848A
(en)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Salt forms of organic compounds
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
AR075204A1
(en)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
DPP-4 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, USEFUL TO TREAT METABOLIC DISEASES IN PEDIATRIC PATIENTS, PARTICULARLY MELLITUS DIABETES TYPE 2
|
EP2391366B1
(en)
|
2009-01-29 |
2012-11-28 |
Novartis AG |
Substituted benzimidazoles for the treatment of astrocytomas
|
JP2012517977A
(en)
|
2009-02-13 |
2012-08-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
An anti-diabetic drug comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other anti-diabetic drugs
|
JP2012518657A
(en)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
Combined anticancer treatment
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
TW201102068A
(en)
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
SI2445903T1
(en)
|
2009-06-26 |
2014-07-31 |
Novartis Ag |
1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(en)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
|
GEP201706639B
(en)
|
2009-08-17 |
2017-03-27 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
KR20120089463A
(en)
|
2009-08-20 |
2012-08-10 |
노파르티스 아게 |
Heterocyclic oxime compounds
|
BR112012008075A2
(en)
|
2009-08-26 |
2016-03-01 |
Novartis Ag |
tetrasubstituted heteroaryl compounds and their use as mdm2 and / or mdm4 modulators
|
CA2773661A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
PT2482812T
(en)
|
2009-10-02 |
2023-01-24 |
Boehringer Ingelheim Int |
Therapeutic uses of pharmaceutical compositions
|
AU2010303780B2
(en)
|
2009-10-09 |
2014-02-20 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
PL389357A1
(en)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Tartaric acids derivatives imatinib salts and process for the preparation thereof
|
MY156209A
(en)
|
2009-11-04 |
2016-01-29 |
Novartis Ag |
Heterocyclic sulfonamide derivatives useful mek inhibitors
|
CN102781237A
(en)
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
Cyclodextrin-based polymers for therapeutic delivery
|
US20120289501A1
(en)
|
2009-11-25 |
2012-11-15 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
KR20210033559A
(en)
|
2009-11-27 |
2021-03-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
CA2781218A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
WO2011070588A1
(en)
|
2009-12-10 |
2011-06-16 |
Arch Pharmalabs Limited |
Process for the preparation of imatinib and salts thereof
|
CU24130B1
(en)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
ISOQUINOLINONES AND REPLACED QUINAZOLINONES
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
BR112012020491A2
(en)
|
2010-02-15 |
2017-10-10 |
Reliance Life Sciences Pvt Ltd |
process for the preparation of alpha form of imatinib mesylate.
|
PL390611A1
(en)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Process for the preparation of polymorphic alpha form and new polymorphic form of imatinib mesylate
|
EP2547671A1
(en)
|
2010-03-15 |
2013-01-23 |
Natco Pharma Limited |
Process for the preparation of highly pure crystalline imatinib base
|
EP2547339A1
(en)
|
2010-03-18 |
2013-01-23 |
Boehringer Ingelheim International GmbH |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
WO2011130918A1
(en)
*
|
2010-04-23 |
2011-10-27 |
上海百灵医药科技有限公司 |
Process for synthesizing imatinib
|
EP2382976A1
(en)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
|
US9186392B2
(en)
|
2010-05-05 |
2015-11-17 |
Boehringer Ingelheim International Gmbh |
Combination therapy
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
EP2582680A1
(en)
|
2010-06-17 |
2013-04-24 |
Novartis AG |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
EA024088B1
(en)
|
2010-06-18 |
2016-08-31 |
КРКА, д.д., НОВО МЕСТО |
Alpha-form of imatinib mesylate, processes for preparation thereof and pharmaceutical composition comprising the same
|
EA029416B1
(en)
*
|
2010-06-21 |
2018-03-30 |
Заклады Фармацеутицне Польфарма Са |
Tablet comprising imatinib or a pharmaceutically acceptable salt thereof and process for the preparation thereof
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
UA112517C2
(en)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES
|
SG186983A1
(en)
|
2010-07-09 |
2013-02-28 |
Genentech Inc |
Anti-neuropilin antibodies and methods of use
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
RU2013110058A
(en)
|
2010-08-11 |
2014-09-20 |
Синтон Б.В. |
PHARMACEUTICAL GRANULATE CONTAINING IMATINIB MESILATE
|
TR201007005A2
(en)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
Imatinib base production method
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
AR083878A1
(en)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
|
TR201010618A2
(en)
*
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
An oral dosage form comprising imatinib and the manufacture of an oral dosage form
|
US8685993B2
(en)
|
2010-12-21 |
2014-04-01 |
Novartis Ag |
Bi-heteroaryl compounds as Vps34 inhibitors
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
JP2014505088A
(en)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
[1,2,4] Triazolo [4,3-b] pyridazine compounds as C-MET tyrosine kinase inhibitors
|
CN106619647A
(en)
|
2011-02-23 |
2017-05-10 |
因特利凯有限责任公司 |
Combination of mtor inhibitors and pi3-kinase inhibitors and uses thereof
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
CZ305457B6
(en)
|
2011-02-28 |
2015-09-30 |
Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. |
Pyrimidine compounds inhibiting formation of nitrogen monoxide and prostaglandin E2, process for their preparation and use
|
CN103492390A
(en)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
Fluorophenyl bicyclic heteroaryl compounds
|
PL394169A1
(en)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
|
EP2508525A1
(en)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
CN103649073B
(en)
|
2011-04-28 |
2016-04-13 |
诺瓦提斯公司 |
17 α-hydroxylase/C 17,20-lyase inhibitor
|
KR101884010B1
(en)
|
2011-05-04 |
2018-07-31 |
어리어드 파마슈티칼스, 인코포레이티드 |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
CN102796110B
(en)
*
|
2011-05-23 |
2016-03-30 |
复旦大学 |
Aniline pyrimidine compound and its production and use
|
IN2014DN00123A
(en)
|
2011-06-09 |
2015-05-22 |
Novartis Ag |
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
KR20140025530A
(en)
|
2011-06-27 |
2014-03-04 |
노파르티스 아게 |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
ITMI20111309A1
(en)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
PREPARATION PROCEDURE OF IMATINIB MESILATO
|
CA2841552C
(en)
|
2011-07-15 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
WO2013035102A1
(en)
|
2011-09-05 |
2013-03-14 |
Natco Pharma Limited |
Processes for the preparation of imatinib base and intermediates thereof
|
BR112014006223A8
(en)
|
2011-09-15 |
2018-01-09 |
Novartis Ag |
6-substituted 3- (quinolin-6-ylthio) - [1,2,4-triazol [4,3-a] pyradines, their uses, pharmaceutical compositions, and combination
|
EP2776035B1
(en)
|
2011-11-01 |
2016-08-10 |
Modgene, Llc |
Compositions and methods for reduction of amyloid-beta load
|
RU2486180C1
(en)
*
|
2011-11-02 |
2013-06-27 |
Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") |
Method for preparing 2-arylamino-4-hetarylpyrimidines
|
JP5992054B2
(en)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
Pyrazolopyrrolidine compound
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CN103159739A
(en)
*
|
2011-12-09 |
2013-06-19 |
天津市国际生物医药联合研究院有限公司 |
1, 4-disubstituted-1, 2, 3-triazole compounds and preparation method thereof
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
EA025322B1
(en)
|
2011-12-22 |
2016-12-30 |
Новартис Аг |
Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
|
EP2794591A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
JP2015503515A
(en)
|
2011-12-23 |
2015-02-02 |
ノバルティス アーゲー |
COMPOUND AND COMPOSITION FOR INHIBITING BCL2 AND BINDING PARTY INTERACTION
|
CN104125953A
(en)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
Compounds for inhibiting interaction of bcl2 with binding partners
|
WO2013096055A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
CA2859873A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
PL226174B1
(en)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Combination therapy of non-small-cell lung carcinoma
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
GB2514285B
(en)
|
2012-02-13 |
2018-07-18 |
Grindeks Jsc |
Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
|
IN2012DE00728A
(en)
|
2012-03-13 |
2015-08-21 |
Fresenius Kabi Oncology Ltd |
|
MX371119B
(en)
|
2012-04-03 |
2020-01-17 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use.
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN104379568A
(en)
|
2012-04-24 |
2015-02-25 |
中外制药株式会社 |
Quinazolinedione derivative
|
SG11201406871UA
(en)
|
2012-04-24 |
2014-11-27 |
Chugai Pharmaceutical Co Ltd |
Benzamide derivative
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013171166A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
|
US9365576B2
(en)
|
2012-05-24 |
2016-06-14 |
Novartis Ag |
Pyrrolopyrrolidinone compounds
|
JP6374862B2
(en)
|
2012-05-24 |
2018-08-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Xanthine derivatives as DPP-4 inhibitors for use in the treatment of autoimmune diabetes, particularly LADA
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
EP2861256B1
(en)
|
2012-06-15 |
2019-10-23 |
The Brigham and Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
WO2014025395A1
(en)
|
2012-08-06 |
2014-02-13 |
Duke University |
Compounds and methods for targeting hsp90
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
CN103664787B
(en)
|
2012-09-17 |
2015-09-09 |
南京圣和药业股份有限公司 |
Alkynes heteroaromatic ring compounds and application thereof
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
JP2015531355A
(en)
|
2012-09-28 |
2015-11-02 |
ハンジョウ ベンシェン ファーマシューティカル シーオー., エルティーディー.Hangzhou Bensheng Pharmaceutical Co., Ltd. |
Pharmaceutical composition for tumor treatment and application thereof
|
EP2903979B1
(en)
*
|
2012-10-04 |
2020-08-19 |
Inhibikase Therapeutics, Inc. |
Novel compounds, their preparation and their uses
|
EP3919069A1
(en)
|
2012-11-05 |
2021-12-08 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
TW201422625A
(en)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
Solid form of dihydro-pyrido-oxazine derivative
|
CN103848812B
(en)
*
|
2012-12-04 |
2016-08-03 |
北大方正集团有限公司 |
The method of refined imatinib
|
CN103044394A
(en)
*
|
2012-12-20 |
2013-04-17 |
北京理工大学 |
Phenyl aminopyrimidine derivant and preparation method and application thereof
|
EP2749271A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014124860A1
(en)
|
2013-02-14 |
2014-08-21 |
Boehringer Ingelheim International Gmbh |
Specific pde4b-inhibitors for the treatment of diabetes mellitus
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
Combination of kinase inhibitors and uses thereof
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
ES2683361T3
(en)
|
2013-05-14 |
2018-09-26 |
Hetero Research Foundation |
Imatinib compositions
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(en)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9657007B2
(en)
|
2013-09-22 |
2017-05-23 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
JP6445573B2
(en)
|
2013-10-17 |
2018-12-26 |
サルタル セラピューティクス エルティーディSartar Therapeutics Ltd |
Compositions containing phosphodiesterase inhibitors for use in the treatment of solid tumors in human patients
|
JP6307088B2
(en)
|
2013-10-23 |
2018-04-04 |
中外製薬株式会社 |
Quinazolinone and isoquinolinone derivatives
|
TW201605450A
(en)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Combination of Mdm2 inhibitor and BRAF inhibitor and their use
|
US10000469B2
(en)
|
2014-03-25 |
2018-06-19 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
JP6517319B2
(en)
|
2014-03-28 |
2019-05-22 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
BR112016022499A2
(en)
|
2014-04-03 |
2017-08-15 |
Invictus Oncology Pvt Ltd |
SUPRAMOLECULAR COMBINATORY THERAPEUTIC PRODUCTS
|
US9630944B2
(en)
|
2014-04-04 |
2017-04-25 |
F.I.S.—Fabbrica Italiana Sintetici S.p.A. |
Process for preparing Imatinib and salts thereof, free of genotoxic impurity F
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
JP6526789B2
(en)
|
2014-07-31 |
2019-06-05 |
ノバルティス アーゲー |
Combination therapy
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
CN105585556A
(en)
*
|
2014-11-13 |
2016-05-18 |
连云港杰瑞药业有限公司 |
Synthetic method of imatinib
|
EP3347097B1
(en)
|
2015-09-11 |
2021-02-24 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
|
WO2017129624A1
(en)
|
2016-01-25 |
2017-08-03 |
Krka, D.D., Novo Mesto |
Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
|
SI3240538T1
(en)
|
2016-03-25 |
2022-02-28 |
Ab Science |
Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
CA3022202A1
(en)
|
2016-06-10 |
2017-12-14 |
Boehringer Ingelheim International Gmbh |
Combinations of linagliptin and metformin
|
EP3257499A1
(en)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Process for preparation of imatinib methanesulfonate capsules
|
CN107652269A
(en)
*
|
2016-07-26 |
2018-02-02 |
江苏豪森药业集团有限公司 |
Methanesulfonic acid fluorine imatinib purification of intermediate method
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
CN107805240A
(en)
*
|
2016-09-08 |
2018-03-16 |
中国科学院合肥物质科学研究院 |
A kind of new PDGFR kinase inhibitors and application thereof
|
RU2019112860A
(en)
|
2016-09-27 |
2020-10-30 |
Серо Терапьютикс, Инк. |
CHIMERIC INTERNALIZING RECEPTOR MOLECULES
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
EP3333162A1
(en)
|
2016-12-12 |
2018-06-13 |
Silesian Catalysts sp. z o.o. |
Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
|
CN107089969B
(en)
*
|
2017-04-26 |
2020-04-24 |
黑龙江鑫创生物科技开发有限公司 |
Method for synthesizing imatinib intermediate
|
MX2020007266A
(en)
|
2017-09-26 |
2020-09-07 |
Cero Therapeutics Inc |
Chimeric engulfment receptor molecules and methods of use.
|
WO2019083962A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and pembrolizumab for treating breast cancer
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
Peptide vaccines and hdac inhibitors for treating multiple myeloma
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
US11602534B2
(en)
|
2017-12-21 |
2023-03-14 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Pyrimidine derivative kinase inhibitors
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
KR20210024441A
(en)
|
2018-03-28 |
2021-03-05 |
세로 테라퓨틱스, 인코포레이티드 |
Expression vectors for chimeric phagocytic receptors, genetically modified host cells, and uses thereof
|
EP3774906A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20210023135A1
(en)
|
2018-03-28 |
2021-01-28 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
AU2019304485A1
(en)
|
2018-07-17 |
2020-12-17 |
Boehringer Ingelheim International Gmbh |
Cardiosafe antidiabetic therapy
|
CN112437666A
(en)
|
2018-07-17 |
2021-03-02 |
勃林格殷格翰国际有限公司 |
Heart and kidney safe antidiabetic therapy
|
WO2020023628A1
(en)
|
2018-07-24 |
2020-01-30 |
Hygia Pharmaceuticals, Llc |
Compounds, derivatives, and analogs for cancer
|
AU2020312840A1
(en)
|
2019-07-15 |
2022-01-20 |
Intas Pharmaceuticals Ltd. |
Pharmaceutical composition of imatinib
|
EP4038097A1
(en)
|
2019-10-03 |
2022-08-10 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
JP2023536346A
(en)
|
2020-08-05 |
2023-08-24 |
エリプシーズ ファーマ リミテッド |
Treatment of Cancer with Cyclodextrin-Containing Polymeric Topoisomerase Inhibitor Conjugates and PARP Inhibitors
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
TW202237638A
(en)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
|
EP4298114A1
(en)
|
2021-02-26 |
2024-01-03 |
Kelonia Therapeutics, Inc. |
Lymphocyte targeted lentiviral vectors
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|